# Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes

Study · id `cardio:ct-nct01140893` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01140893](<https://clinicaltrials.gov/study/NCT01140893>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01140893

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 110 participants.

## Technical summary

Registry record NCT01140893. Randomized; quadruple masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2017-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 110 participants (planned count; ClinicalTrials.gov record NCT01140893, source copy `cardio:ctgov-nct01140893-2016-08-23`, retrieved 2026-10-26)
- Start date: 2010-11 (registry gives no type) (ClinicalTrials.gov record NCT01140893, source copy `cardio:ctgov-nct01140893-2016-08-23`, retrieved 2026-10-26)
- Primary completion: 2017-05 (anticipated) (ClinicalTrials.gov record NCT01140893, source copy `cardio:ctgov-nct01140893-2016-08-23`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: France (ClinicalTrials.gov record NCT01140893, source copy `cardio:ctgov-nct01140893-2016-08-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01140893-2016-08-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes
- Acronym: EXEPUMP
- Condition: Type 2 Diabetes
- Intervention (Drug): Exenatide
- Intervention (Drug): Placebo
- Lead sponsor: University Hospital, Caen
- Lead sponsor class: OTHER
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University Hospital, Caen (`cardio:org-university-hospital-caen`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 497b3b203f946bfc1879ea690447ef2a0201a408e4d65e62f0f996802c11ebd5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
